Oxybate ( DrugBank: Oxybate )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病3
149片側痙攣・片麻痺・てんかん症候群1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04006925
(ClinicalTrials.gov)
September 10, 201927/6/2019Treatment of REM Sleep Behavior Disorder (RBD) With Sodium OxybateSodium Oxybate in Treatment-Resistant REM Sleep Behavior Disorder (RBD): A Randomized Placebo-Controlled TrialREM Sleep Behavior Disorder;Parkinson DiseaseDrug: Sodium Oxybate;Other: PlaceboStanford UniversityJazz PharmaceuticalsCompleted40 Years85 YearsAll24Phase 4United States
2NCT02111122
(ClinicalTrials.gov)
April 20148/4/2014Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's DiseaseA Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's DiseaseSleep-wake Disturbances in Motor-phase Parkinson's DiseaseDrug: Sodium Oxybate;Drug: PlaceboChristian BaumannNULLCompleted18 Years90 YearsAll16Phase 2Switzerland
3NCT00641186
(ClinicalTrials.gov)
September 200418/3/2008Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's DiseaseParkinson DiseaseDrug: sodium oxybateBaylor College of MedicineJazz PharmaceuticalsCompleted30 Years75 YearsAll30Phase 2NULL

149. 片側痙攣・片麻痺・てんかん症候群


臨床試験数 : 25 薬物数 : 35 - (DrugBank : 13) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 22
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00931164
(ClinicalTrials.gov)
August 200930/6/2009Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial)Alternating Hemiplegia of ChildhoodDrug: Sodium OxybateUniversity of UtahAlternating Hemiplegia of Childhood Foundation;Jazz PharmaceuticalsCompleted6 Months25 YearsAll6Phase 1/Phase 2United States